Bausch + Lomb Corp (BLCO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bausch + Lomb Corp (BLCO) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$137.00 Million ≈ $99.10 Million USD) by net assets (CA$6.50 Billion ≈ $4.70 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Bausch + Lomb Corp for the company's overall valuation and market capitalisation.
Bausch + Lomb Corp - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Bausch + Lomb Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bausch + Lomb Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bausch + Lomb Corp ranked by their cash flow conversion efficiency. Explore Bausch + Lomb Corp cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yantai Moon Co Ltd
SHE:000811
|
0.046x |
|
Arcosa Inc
NYSE:ACA
|
0.027x |
|
Loar Holdings Inc.
NYSE:LOAR
|
0.022x |
|
Soochow Securities Co Ltd
SHG:601555
|
0.336x |
|
Hyundai Mipo Dockyard
KO:010620
|
0.085x |
|
Zheshang Securities Co Ltd
SHG:601878
|
0.185x |
|
Trade Desk Inc
NASDAQ:TTD
|
0.125x |
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
0.022x |
Annual Cash Flow Conversion Efficiency for Bausch + Lomb Corp (2019–2024)
The table below shows the annual cash flow conversion efficiency of Bausch + Lomb Corp from 2019 to 2024. View BLCO stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$6.54 Billion ≈ $4.73 Billion |
CA$232.00 Million ≈ $167.83 Million |
0.035x | +1543.12% |
| 2023-12-31 | CA$6.92 Billion ≈ $5.01 Billion |
CA$-17.00 Million ≈ $-12.30 Million |
-0.002x | -105.06% |
| 2022-12-31 | CA$7.10 Billion ≈ $5.14 Billion |
CA$345.00 Million ≈ $249.57 Million |
0.049x | -47.68% |
| 2021-12-31 | CA$9.40 Billion ≈ $6.80 Billion |
CA$873.00 Million ≈ $631.51 Million |
0.093x | +77.67% |
| 2020-12-31 | CA$9.99 Billion ≈ $7.23 Billion |
CA$522.00 Million ≈ $377.61 Million |
0.052x | -34.38% |
| 2019-12-31 | CA$10.03 Billion ≈ $7.26 Billion |
CA$799.00 Million ≈ $577.98 Million |
0.080x | -- |
About Bausch + Lomb Corp
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily d… Read more